Figure 2. Immune-mediated suppression of tumor growth by Kiatomab in pulmonary metastasis models. (A) Different doses of Kiatomab or control Ig were co-cultured with tumor cells for 72 h. The viability of cells was determined by MTS assay. (B-E) 2×10⁵ tumor cells were i.v. injected into (B) BALB/c, (C) C57BL/6, and (D, E) NOD/SCID mice. One day later, the indicated doses of Kiatomab (10 µg for NOD/SCID mice), its F(ab′)2 fragment, or control Ig were i.p. injected into tumor-bearing mice. On day 14 after tumor injection, lungs were extracted and the number of metastatic nodules on the lung surface was counted (n=7). (E) Tumor-bearing mice were treated with 10 µg of Kiatomab and control Ig at the indicated time points.

Data are representative of three independent experiments and shown as mean±SEM.

^*,#p<0.05; ^**,##p<0.01; ^***p<0.001 versus corresponding control Ig-treated groups by Mann-Whitney U test.